health canada approval zepbound tirzepatide obesity canada 2024 2025 Weight-loss drug approved to treat sleep apnea in Health Canada has approved Wegovy®

Dehydration and kidney strain: One of the most common side effects of Tirzepatide is gastrointestinal distress, including nausea, vomiting, and diarrhea

However, for metabolically healthy women considering GLP-1s for modest weight loss, the risks may outweigh the benefits

Impact on Weight Loss One of the primary uses of tirzepatide is for weight management

People with a history of pancreatitis or severe stomach or intestinal problems are advised not to take incretin-based therapies like GLP-1s

Serious but rare risks include pancreatitis, gallbladder disease, and hypoglycaemia (particularly when used with insulin or sulfonylureas)